Find out the Buzz on all the Hottest stocks at: http://www.OTCtipReporter.com
BEVERLY HILLS, Calif., Aug. 29, 2012 Eaton Scientific Systems, Ltd. ("Eaton Scientific" or the "Company"), a wholly owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to announce that the Company has retained clinical trial veteran Dr. David L. Stark, D.C., Q.M.E., CCRA, to develop and oversee FDA compliant trials of Tropine 3 for non-hormonal treatment of hot flashes in menopausal women.
"The addition of Dr. Stark to the Eaton Scientific team gives a significant boost to our efforts to develop, validate, and monetize Tropine 3 as a safe and effective non-hormonal treatment of hot flashes in menopausal women," stated Michael Borkowski, CEO and President of Eaton Scientific. "We except that he will be instrumental in all aspects of our planned clinical trials going forward especially in regard to trial development, implementation, and overall FDA compliance."
In addition to his significant accomplishments on the industry side of clinical drug and device development, Dr. Stark has experience with the FDA with a major focus on Investigational New Drugs (IND), New Drug Applications (NDA), and 510K applications. Prior to his employment at NICR, Dr. Stark was the President and Chief Executive Officer of Powder Ice, a medical products company. Additionally, Dr. Stark is a California state licensed Qualified Medical Examiner and Certified Clinical Research Associate.
Disclosure: OTCtipReporter.com Has NOT been compensated to profile PRTN. We Own NO Shares.
We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by OTC Tip Reporter. Please be advised that the information provided May or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed. To view a complete disclaimer, visit: http://www.otctipreporter.com/disclaimer.htm